MedTrace Logo

Study of COVID-19 DNA Vaccine (AG0302-COVID19)

NCT04527081 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-10-04

No results posted yet for this study

Summary

This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy adult volunteers.

Conditions

Interventions

BIOLOGICAL

AG0302-COVID19

2.0 mg of AG0302-COVID19 twice at 2-week intervals

BIOLOGICAL

AG0302-COVID19

2.0 mg of AG0302-COVID19 twice at 4-week intervals

BIOLOGICAL

AG0302-COVID19

2.0 mg of AG0302-COVID19 three times at 2-week intervals

Sponsors & Collaborators

  • AnGes, Inc.

    lead INDUSTRY

Principal Investigators

  • AnGes, Inc. Clinical Development · AnGes, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2020-11-09
Completion
2021-09-24

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04527081 on ClinicalTrials.gov